Lysine 53 Acetylation of Cytochrome c in Prostate Cancer: Warburg Metabolism and Evasion of Apoptosis by Bazylianska, Viktoriia et al.
Wayne State University 
Biochemistry and Molecular Biology Faculty 
Publications 
Department of Biochemistry and Molecular 
Biology 
4-1-2021 
Lysine 53 Acetylation of Cytochrome c in Prostate Cancer: 
Warburg Metabolism and Evasion of Apoptosis 
Viktoriia Bazylianska 
Center for Molecular Medicine and Genetics, Wayne State University School of Medicine 
Hasini A. Kalpage 
Center for Molecular Medicine and Genetics, Wayne State University School of Medicine 
Junmei Wan 
Center for Molecular Medicine and Genetics, Wayne State University School of Medicine 
Asmita Vaishnav 
Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine 
Gargi Mahapatra 
Center for Molecular Medicine and Genetics, Wayne State University School of Medicine 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wayne.edu/med_biochem 
 Part of the Biochemistry Commons, and the Molecular Biology Commons 
Recommended Citation 
Bazylianska,V.; Kalpage, H.A.; Wan, J.; Vaishnav, A.; Mahapatra, G.; Turner, A.A.; Chowdhury, D.D.; Kim, K.; 
Morse, P.T.; Lee, I.; et al. Lysine 53 Acetylation of Cytochrome c in Prostate Cancer: Warburg Metabolism 
and Evasion of Apoptosis. Cells 2021, 10, 802. https://doi.org/10.3390/cells10040802 
This Article is brought to you for free and open access by the Department of Biochemistry and Molecular Biology at 
DigitalCommons@WayneState. It has been accepted for inclusion in Biochemistry and Molecular Biology Faculty 
Publications by an authorized administrator of DigitalCommons@WayneState. 
Authors 
Viktoriia Bazylianska, Hasini A. Kalpage, Junmei Wan, Asmita Vaishnav, Gargi Mahapatra, Alice A. Turner, 
Dipanwita Dutta Chowdhury, Katherine Kim, Paul T. Morse, Icksoo Lee, Joseph S. Brunzelle, Lisa Polin, 
Prabal Subedi, Elisabeth I. Heath, Izabela Podgorski, Katrin Marcus, Brian FP Edwards, and Maik 
Hu ̈ttemann 
This article is available at DigitalCommons@WayneState: https://digitalcommons.wayne.edu/med_biochem/17 
cells
Article
Lysine 53 Acetylation of Cytochrome c in Prostate Cancer:
Warburg Metabolism and Evasion of Apoptosis
Viktoriia Bazylianska 1,2,†, Hasini A. Kalpage 1,†, Junmei Wan 1,†, Asmita Vaishnav 2, Gargi Mahapatra 1,2,‡,
Alice A. Turner 1,2, Dipanwita Dutta Chowdhury 2, Katherine Kim 1, Paul T. Morse 1 , Icksoo Lee 1,3,
Joseph S. Brunzelle 4, Lisa Polin 5, Prabal Subedi 6, Elisabeth I. Heath 5, Izabela Podgorski 7, Katrin Marcus 6 ,
Brian F.P. Edwards 2 and Maik Hüttemann 1,2,*


Citation: Bazylianska, V.; Kalpage,
H.A.; Wan, J.; Vaishnav, A.;
Mahapatra, G.; Turner, A.A.;
Chowdhury, D.D.; Kim, K.; Morse,
P.T.; Lee, I.; et al. Lysine 53
Acetylation of Cytochrome c in
Prostate Cancer: Warburg
Metabolism and Evasion of
Apoptosis. Cells 2021, 10, 802.
https://doi.org/10.3390/cells10040802
Academic Editor: Tatiana V. Vygodina
Received: 5 March 2021
Accepted: 1 April 2021
Published: 3 April 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Center for Molecular Medicine and Genetics, School of Medicine, Wayne State University,
Detroit, MI 48201, USA; viktoriiabazylianska@wayne.edu (V.B.); hkalpage@med.wayne.edu (H.A.K.);
am4472@wayne.edu (J.W.); gmahapat@wakehealth.edu (G.M.); afturner@med.wayne.edu (A.A.T.);
katiedcds@gmail.com (K.K.); morsepa@wayne.edu (P.T.M.); icksoolee@dankook.ac.kr (I.L.)
2 Department of Biochemistry, Microbiology, and Immunology, School of Medicine, Wayne State University,
Detroit, MI 48201, USA; vaishnav@med.wayne.edu (A.V.); dipanwita@wayne.edu (D.D.C.);
brian.edwards@wayne.edu (B.F.P.E.)
3 College of Medicine, Dankook University, Cheonan-si, Chungcheongnam-do 31116, Korea
4 Life Sciences Collaborative Access Team, Center for Synchrotron Research, Northwestern University,
Argonne, IL 60439, USA; j-brunzelle@northwestern.edu
5 Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA;
polinl@karmanos.org (L.P.); heathe@karmanos.org (E.I.H.)
6 Medical Proteomics/Bioanalytics-Center, Ruhr-University Bochum, 44789 Bochum, Germany;
sprabal@gmail.com (P.S.); katrin.marcus@ruhr-uni-bochum.de (K.M.)
7 Department of Pharmacology, Wayne State University, Detroit, MI 48201, USA; ipodgors@med.wayne.edu
* Correspondence: mhuttema@med.wayne.edu; Tel.: +1-313-577-9150; Fax: +1-313-577-5218
† These authors contributed equally to this work.
‡ Present address: Department of Internal Medicine, Section on Gerontology and Geriatric Medicine,
Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA.
Abstract: Prostate cancer is the second leading cause of cancer-related death in men. Two classic
cancer hallmarks are a metabolic switch from oxidative phosphorylation (OxPhos) to glycolysis,
known as the Warburg effect, and resistance to cell death. Cytochrome c (Cytc) is at the intersection
of both pathways, as it is essential for electron transport in mitochondrial respiration and a trigger
of intrinsic apoptosis when released from the mitochondria. However, its functional role in cancer
has never been studied. Our data show that Cytc is acetylated on lysine 53 in both androgen
hormone-resistant and -sensitive human prostate cancer xenografts. To characterize the functional
effects of K53 modification in vitro, K53 was mutated to acetylmimetic glutamine (K53Q), and to
arginine (K53R) and isoleucine (K53I) as controls. Cytochrome c oxidase (COX) activity analyzed
with purified Cytc variants showed reduced oxygen consumption with acetylmimetic Cytc compared
to the non-acetylated Cytc (WT), supporting the Warburg effect. In contrast to WT, K53Q Cytc had
significantly lower caspase-3 activity, suggesting that modification of Cytc K53 helps cancer cells
evade apoptosis. Cardiolipin peroxidase activity, which is another proapoptotic function of the
protein, was lower in acetylmimetic Cytc. Acetylmimetic Cytc also had a higher capacity to scavenge
reactive oxygen species (ROS), another pro-survival feature. We discuss our experimental results in
light of structural features of K53Q Cytc, which we crystallized at a resolution of 1.31 Å, together
with molecular dynamics simulations. In conclusion, we propose that K53 acetylation of Cytc affects
two hallmarks of cancer by regulating respiration and apoptosis in prostate cancer xenografts.
Keywords: cytochrome c; prostate cancer; acetylation; Warburg effect; cytochrome c oxidase; apopto-
sis; reactive oxygen species; cell signaling
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1. Introduction
Cytochrome c (Cytc) is a globular 104 amino acid heme protein that orchestrates
cellular life and death decisions. It functions as an electron carrier in the electron transport
chain (ETC) and as a trigger of apoptosis when released from the mitochondria [1,2]. Cytc
transfers single electrons from complex III (bc1 complex) to complex IV (cytochrome c
oxidase, COX) where oxygen is reduced to water in the ETC. Cytc is an indispensable
molecule for ATP production and cell survival. Cytc also acts as a signaling molecule
for apoptosis upon release from the mitochondria, by interacting with apoptosis protease
activating factor-1 (Apaf-1) and forming an active apoptosome, which initiates caspase-9
activity and the downstream caspase cascade. Reactive oxygen species (ROS) are a known
trigger of intrinsic apoptosis. Being an electron carrier, Cytc plays a role in ROS scavenging
and ROS formation. In addition, Cytc acts as a catalyst for cardiolipin peroxidation [1,2],
which facilitates the release of Cytc from the mitochondria, promoting apoptosis [3–5].
Cytc is an ideal target of cancer cell signaling due its two primary functions in oxidative
phosphorylation (OxPhos) and cell death via intrinsic apoptosis [6]. Most cancer cells rely
more heavily on aerobic glycolysis instead of OxPhos, a phenomenon referred to as the
“Warburg effect”. Cancer cells undergo metabolic reprogramming in order to promote
anabolic biomass production needed for cell proliferation [7]. Deregulation of cellular
energetics and resistance to cell death are both major hallmarks of cancer [8]. Cytc is
a protein that is at the intersection of pathways leading to both these mechanisms of
carcinogenesis. We have recently shown that Cytc is posttranslationally modified in vivo
by phosphorylation in mammalian heart [9], liver [10], kidney [11,12], and brain [13]
under normal conditions on five distinct residues, and that these modifications decisively
regulate respiration and apoptosis. To date, no study has investigated how structural and
functional changes of Cytc may affect tumor metabolism in cancer in general or in prostate
cancer specifically.
According to the National Cancer Institute, in 2020 there were an estimated 191,930
new cases of prostate cancer, making it the most common cancer in men. In addition, there
were about 33,330 deaths due to prostate cancer, making it the second leading cause of can-
cer related death in men in the US [14]. Prostate cancer can be hormone responsive, where
castration leads to tumor regression. Androgen deprivation therapy (ADT) is the standard
of care for prostate cancer. Cancers that respond to ADT are called castrate-sensitive
tumors versus castrate-resistant tumors, which resist ADT and are more aggressive and
metastatic [15]. Prostate cancer is highly heterogeneous, and little is known about the
role of metabolic reprogramming in disease progression [16]. Interestingly, mitochondrial
dysfunction is known to be associated with prostate cancer aggressiveness [17].
In this study, we analyzed the posttranslational modifications (PTMs) of Cytc in
4 castrate-resistant and 4 castrate-sensitive prostate tumor xenografts. We identified that
Cytc was acetylated on lysine 53 (K53) in all 8 xenografts. Cytc is a highly basic protein
that contains 18 lysine residues, which account for about 17% of the protein. We propose
that the specific identification of a single modified residue, via K53 acetylation on Cytc, is
important and relevant to prostate cancer pathogenesis. Therefore, we characterized K53
acetylation in vitro using an acetylmimetic glutamine mutant Lys53Gln (K53Q) along with
non-acetylated WT, Lys53Arg (K53R), and nonpolar Lys53Ile (K53I) Cytc. Our experiments
show that the K53Q acetylmimetic replacement of Cytc promotes Warburg metabolism by
lowering COX activity, evades apoptosis by lowering caspase-3 activity and cardiolipin
peroxidase activity, and by increasing ROS scavenging.
2. Methods
2.1. Prostate Cancer Xenografts and Mass Spectrometry
Androgen-independent PC3 cells derived from a bone metastasis of a high-grade
adenocarcinoma, and androgen-sensitive VCaP cells derived from a vertebral metastasis,
were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). Cells
were cultured in DMEM supplemented with 10% FBS, 10 mM HEPES, and 100 U/mL
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penicillin-streptomycin in a 37 ◦C humidified incubator ventilated with 5% CO2. Both
cell lines were authenticated by the WSU Genomics facility and routinely tested for my-
coplasma using MycoFluor Mycoplasma Detection Kit (Thermo Fisher Scientific, Waltham,
MA, USA) and LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich, St. Louis, MO,
USA). All experiments involving mice were performed in accordance with the protocol
approved by the Institutional Animal Investigational Committee of Wayne State Univer-
sity and NIH guidelines. Subcutaneous injections of PC3 and VCaP cell suspensions (in
PBS/Cultrex, R&D systems, Minneapolis, MN, USA) into SCID mice were performed by
the Animal Model and Therapeutics Evaluation Core (AMTEC) at Wayne State University.
The resulting tumors were harvested and immediately snap-frozen in liquid nitrogen and
stored at −80 ◦C. Cytc was enriched by immunoprecipitation as previously described [11].
After immunoprecipitation, enriched samples were run on a 10% tris-tricine gel. Bands
corresponding to ~12 kDa were cut. Protein digestion from the gel pieces was performed by
addition of trypsin (Serva Electrophoresis, Heidelberg, Germany) in a 1:50 (trypsin:protein)
ratio at 37 ◦C for 16 h. Digestion was halted with the addition of 1:1 (v/v) solution of
acetonitrile (MeCN, Sigma-Aldrich Chemie, Schnelldorf, Germany) and 0.1% trifluoroacetic
acid (TFA, Sigma-Aldrich). The samples were sonicated for 10 min twice, and the super-
natants were dried in a rotational vacuum centrifuge (SpeedDry RVC 2-25 Cdplus, Martin
Christ Gefriertrocknungsanlagen GmbH, Osterode, Germany). The dried samples were
resuspended in 0.1% TFA and the peptide amount was calculated by amino acid analysis.
Briefly, the samples were dried in a glass vial and hydrolyzed (150 ◦C, 1 h in helium)
using 6 M HCl (Sigma-Aldrich Chemie, Schnelldorf, Germany). Derivatization (56 ◦C,
10 min) was performed with a reagent containing 10 pmol Norvaline (Waters, Manchester,
UK). The individual amino acids were quantified on an ACQUITY-UPLC system (Waters,
Manchester, UK) using norvaline as an internal calibrant. The peptides were separated on
an Ultimate 3000 RSLC nano system (Dionex, Idstein, Germany), containing a C18 trap
column (100 µm × 2 cm, particle size 5 µm, pore size 100 Å, flow rate 30 µL/min, Thermo
Fisher Scientific, Bremen, Germany), and an analytical C18 column (75 µm× 50 cm, particle
size 2 µm, pore size 100 Å, flow rate 0.4 µL/min, Thermo Fisher, Bremen, Germany), which
was coupled to an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific). Solvent
(A): 0.1% formic acid in H2O and solvent (B): MeCN, 0.1% formic acid in H2O were used
for separation of the peptides, where the gradient started with 4% B (5 min) to 40% B
(95–100 min) and finally returning to 4% B at 120 min. For MS measurements, capillary
flow (275 ◦C, 1500 V) was used and full spectra between 300 and 2000 m/z (resolution
60,000 at 200 m/z) were recorded. Automated gain control of 1e6 and maximum injection
time of 500 ms were set. For internal calibration, polydimethylcyclosiloxane (m/z 445.120)
was used. The peptides were fragmented in a high-energy collisional dissociation cell
with a normalized collision energy of 35%, a minimum mass of 130 m/z and an isolation
window of ±1 m/z. An automated gain control of 1e4 and maximum injection time of
100 ms were set for the MS/MS analyses of the fragmented peptides.
For the identification of peptide-modifications, the raw MS files were analyzed us-
ing Proteome Discoverer 1.4 software (Thermo Fisher Scientific) with the Mascot V2.3
search algorithm (Matrix Science, London, UK) [18]. Searches were performed against
the Uniprot/Swissprot database. Search parameters were peptide mass 400–10,000 Da,
mass tolerance of 5 ppm, fragment mass tolerance of 20 amu, a maximum of 2 uncleaved
sites, dynamic oxidation (methionine), dynamic methylation (lysine, C-term), and dy-
namic acetylation (lysine, N-term). After algorithmic identification, assignments were
manually verified.
2.2. Immunoprecipitation and Western Blotting
Frozen PC3 and VCaP xenografts, normal human kidney and kidney cancer tissues,
lung cancer tissues, and normal human prostate and prostate cancer tissues were cut into
small pieces on dry-ice, lysed with homogenization buffer (50 mM Tris-Cl, pH 7.5, 1 mM
EGTA, 1% Triton-X 100, 1 mM sodium orthovanadate, 50 mM KF, 5 mM sodium pyrophos-
Cells 2021, 10, 802 4 of 21
phate, 0.27 M sucrose), supplemented with a protease inhibitor cocktail (#P8340, Sigma-
Aldrich), and homogenized using a Teflon Dounce homogenizer by applying 60 strokes.
Homogenates were centrifuged at 22,000× g at 4 ◦C for 30 min and the total protein con-
centration of the tissue lysates were quantitated using the DC protein assay kit (BioRad,
Hercules, CA, USA). Cytc was immunoprecipitated from 1 mg total protein lysate with 2 µg
mouse anti-Cytc antibody (#556432, clone 6H2.B4, BD Pharmingen, San Jose, CA, USA)
along with anti-mouse IgG1 kappa isotype antibody as a control (# 14-4714-81, Thermo
Fisher Scientific). Similarly, Cytc was immunoprecipitated from cultured PC3, VCaP, and
MDA-MB-231 cells with minor modification. Briefly, the cells were harvested by scraping
and lysed by sonication in lysis buffer (50 mM Tris-Cl, pH 7.5, 1 mM EGTA, 1% Triton-X
100, 1 mM sodium orthovanadate, 50 mM KF, 5 mM sodium pyrophosphate). Immuno-
precipitated Cytc samples together with recombinant human Cytc (1 µg) were resolved
on a 10% tris-tricine gel and transferred onto a pre-wet PVDF membrane. The blots were
probed with a 1:1,000 dilution of HRP-conjugate acetylated-lysine (Ac-K-100) MultiMab
rabbit mAb mix (#6952, CST, Danvers, MA, USA) in 5% BSA or mouse anti-Cytc antibody
with a 1:4000 dilution (#556433, clone 7H8.2C12, BD Pharmingen) in 5% milk, followed
by 1:10,000 dilution of anti-mouse IgG conjugated with HRP (#NA93IV, GE Healthcare,
Chicago, IL, USA). Signal was obtained after addition of HyGLO ECL reagent (#E-2500,
Denville Scientific Inc., Metuchen, NJ, USA).
2.3. Generation of Cytc Variants
WT rodent Cytc (mouse/rat Cytc protein sequences are identical), cloned into the
bacterial expression plasmid pLW01 [19], was used to generate non-acetylated K53R,
acetylmimetic K53Q, and nonpolar K53I Cytc variants using the QuikChange II site-directed
mutagenesis kit (Agilent technologies, Santa Clara, CA, USA). The following mutagenesis
primers were used to amplify the plasmid. K53R forward: 5′-CTT ACA CAG ATG CCA
ACA GGA ACA AAG GTA TCA CC-3′, K53R reverse: 5′-GGT GAT ACC TTT GTT
CCT GTT GGC ATC TGT GTA AG-3’, K53Q forward: 5′-CTT ACA CAG ATG CCA
ACC AGA ACA AAG GTA TCA CC-3′, K53Q reverse: 5′-GGT GAT ACC TTT GTT
CTG GTT GGC ATC TGT GTA AG-3′, K53I forward: 5′-CTT ACA CAG ATG CCA ACA
TTA ACA AAG GTATCA CCT G-3′, K53I reverse: 5′-CAG GTG ATA CCT TTG TTA
ATG TTG GCA TCT GTG TAA G-3′. The PCR product was incubated for one hour at
37 ◦C with DpnI endonuclease (QuikChange II site-directed mutagenesis kit) to digest
the methylated parental DNA, leaving the newly synthesized mutated DNA intact. The
mutant plasmids were then transformed into XL10-Gold ultracompetent cells (QuikChange
II site-directed mutagenesis kit) according to manufacturer’s protocol. Single bacterial
colonies were picked for each mutant and all plasmids from overnight cultures were
purified using QIAprep spin miniprep kit (#27106, Qiagen, Valencia, CA, USA) following
the manufacturer’s protocol. NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific)
was used to quantify and assess the purity of DNA. The Cytc mutant plasmids were
confirmed by sequencing.
2.4. Bacterial Overexpression and Purification of Cytc Variants
Sequence-confirmed pLW01 mutant plasmids were transformed into competent C41(DE3)
E. coli cells (#60442-1, Lucigen, Middleton, WI, USA) for protein overexpression and
purification, using the heat shock method as described in the manufacturer’s protocol.
Transformed bacteria were plated on LB-agar plates containing 100 µg/mL ampicillin.
Selected clones were inoculated in 10 mL of LB medium with 100 µg/mL ampicillin and
cultured overnight at 37 ◦C. The overnight cultures were transferred into 1L of terrific broth
medium (Research Products International, Mount Prospect, IL, USA) with 100 µg/mL of
carbenicillin. The cultures were grown until an OD600 of 1 was reached, and 100 µM IPTG
was added to induce Cytc expression. The induced cultures were incubated for 6 h to allow
protein expression and the bacterial cells were pelleted by centrifugation at 8400× g, for
40 min at 4 ◦C. The pellets were stored at −80 ◦C until use. The bacterial pellets were
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thawed and resuspended in lysis buffer (20 mM phosphate buffer, pH 7.4), supplemented
with protease inhibitor cocktail (#P8340, Sigma-Aldrich). For 10 g of pellet, 100 mL of
lysis buffer was added. The cells were lysed by a French pressure cell press (AMINCO,
American Instrument Co., Silver Spring, MD, USA). To remove cell debris, the cell lysates
were centrifuged for 45 min at 26,200× g. The supernatant was adjusted to pH 7.5 and
diluted with ddH2O until a conductivity of 4 mS/cm was reached and matched with the
DE52 cellulose anion-exchange column (Whatman, Piscataway, NJ, USA). Adjusted super-
natant was passed through the equilibrated DE52 column. Most of the bacterial proteins
were bound to the column, and Cytc was collected in the flow-through. The collected
solution was adjusted to pH 6.5 and conductivity was increased by the addition of KH2PO4
buffer until it reached a conductivity of 6 mS/cm and matched with the CM52 cellulose
cation-exchange column (Whatman). The adjusted flow-through was passed through the
equilibrated CM52 column, allowing the positively charged Cytc to bind the CM52 column.
After washing the CM52 column, the bound Cytc was eluted with high salt buffer (0.5 M
NaCl in 40 mM phosphate buffer, pH 6.5). Cytc fractions were desalted and concentrated
by centrifugation using Amicon ultra-15 3 k units (#UFC901008, Millipore, Billerica, MA,
USA). The purity of the protein was determined by spectrophotometer and by running
1 µg of each Cytc variant on a 10% Tris-tricine gel, followed by Coomassie blue staining.
2.5. Determination of the Concentration of Cytc Variants
Diluted Cytc variants were oxidized with a few granules of potassium ferricyanide
K3Fe(CN)6 and reduced with a few granules of sodium dithionite (Na2S2O4). Absorption
spectra were recorded on a Jasco V-570 double beam spectrophotometer (2 nm bandwidth,
200 nm/min scanning speed) using a 0.1 mm path length quartz cuvette. In order to
determine concentration, the absorbance at 550 nm was recorded for reduced and oxi-
dized Cytc. The Cytc concentration in mM was calculated using the following equation:
(A550red−A550oxi)/19.6 mM/cm × 1 cm × dilution factor.
2.6. COX Activity Measurement
Regulatory-competent bovine liver COX (3 µM) was dialyzed at 4 ◦C in the presence
of cardiolipin and 0.1 mM ATP in COX measuring buffer (10 mM K-HEPES pH 7.4, 40 mM
KCl, 2 mM EGTA, 10 mM KF, 1% Tween-20), as previously described [11], to remove cholate
bound to COX during enzyme purification. Oxygen consumption of COX (30 nM) upon
titration of Cytc variants (0–25 µM) was analyzed using a Clark-type oxygen electrode
(Oxygraph system, Hansatech, Pentney, UK) at 25 ◦C in 220 µL of COX measuring buffer
in the presence of 20 mM ascorbate as the electron donor. The oxygen consumption rate
was recorded and analyzed with the Oxygraph software (Hansatech). The activity of COX
was expressed as turnover number (s−1).
2.7. Caspase-3 Activity Measurement
Caspase-3 activity was assayed using an in vitro cell-free apoptosis detection system
with cytosolic extracts from HeLa cells as previously described [19,20]. Cells were cultured
in eight 75 cm2 flasks, harvested by trypsinization, and washed twice with cold PBS,
followed by one wash with cytosolic extraction buffer (CEB: 20 mM K-HEPES, pH 7.5,
1.5 mM MgCl2, 10 mM KCl, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 100 µM PMSF). The
cell pellet was resuspended in CEB, and the suspension was transferred to a Dounce
homogenizer, allowing it to swell in the hypotonic CEB for 15 min on ice. Cells were
disrupted by 20 strokes with a B-type glass pestle. Lysates were centrifuged at 15,000× g
for 15 min at 4 ◦C to collect the cytosolic extract. Protein concentration was determined
using the DC protein assay kit (Bio-Rad, Hercules, CA, USA). Caspase-3 activity was
measured using the EnzChek caspase-3 assay kit (Invitrogen, Carlsbad, CA, USA). Artificial
caspase-3 substrate rhodamine 110-linked DEVD tetrapeptide (Z-DEVD R110), which
fluoresces upon cleavage by caspase-3, was used to determine enzyme activity. Cytosolic
extracts at a protein concentration of 2 mg/mL were incubated with recombinant K53
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Cytc variants (15 µg/mL) along with 1 mM ATP for 2.5 h at 37 ◦C. Caspase-3 inhibitor
(Ac-DEVD-CHO) was used as a negative control. Fluorescence was measured using a
Fluoroskan Ascent FL plate reader (Labsystems, Thermo Fischer Scientific) as previously
described [12]. Fluorescence readings from cytosolic extracts without Cytc were subtracted
as a background. Data were presented as a % of change compared to WT.
2.8. Rate of Oxidation Measurement
Rate of oxidation was measured as previously described [11,21]. Briefly, Cytc variants
were reduced with Na2S2O4, and the proteins were separated from the reductant by passing
through NAP-5 columns (#17-0853-02, GE Healthcare, Piscataway, NJ, USA). Oxidizing
agent H2O2 (50 µM) was added to Cytc (15 µM) in 0.2 M Tris-Cl, pH 7.0. After 10 s of H2O2
addition, the decrease of the absorption peak at 550 nm was measured. The amount of
oxidized Cytc was calculated as described above to calculate the rate of Cytc oxidation (s−1).
2.9. Rate of Reduction by Superoxide
The hypoxanthine/xanthine oxidase reaction system was used to generate superoxide
in a cuvette as described [22,23] with some modifications. K53 Cytc variants were oxidized
with K3Fe(CN)6 and desalted on a NAP-5 column (GE Healthcare). The reaction consisted
of 4 µM ferri-Cytc, 100 µM hypoxanthine, and 14.2 nM catalase in 1X PBS. After obtaining
the initial spectrophotometric reading at 550 nm, 181.5 nM xanthine oxidase was quickly
added to the cuvette to initiate the reaction. The 550 nm absorbance was measured at 30 s.
The concentration of reduced Cytc was calculated as described above and the rate of Cytc
reduction by superoxide was determined. Superoxide dismutase 2 (925 nM) was used
as a negative control that rapidly converts superoxide into H2O2. All the reagents were
purchased from Sigma unless otherwise stated.
2.10. Cardiolipin Peroxidase Activity Measurement
The cardiolipin peroxidase activity of Cytc was measured as previously described [11]
with modifications. Liposomes containing 0%, 20%, 30%, and 50% of 18:1 tetraoleoyl-
cardiolipin (TOCL) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were generated.
Lyophilized DOPC was solubilized in chloroform to prepare a working stock of 10 µg/µL.
The required volume of solubilized DOPC for each liposome was added to the tubes
containing TOCL solubilized in chloroform, and both lipids were evaporated under nitro-
gen to remove the solvent. Lipids were resuspended in 20 mM K-Hepes buffer, pH 7.2,
and liposomes were prepared by sonication for 30 s on ice, 5 times, with 1 min intervals.
Liposomes (25 µM) were incubated in a 96-well plate with 1 µM Cytc in the presence of
20 mM K-Hepes. After addition of Cytc, the plate was incubated at room temperature for
10 min to allow the association and equilibration of Cytc-cardiolipin binding. Fluorescence
of resorufin, the oxidation product of Amplex red, was detected using a Fluoroskan Ascent
microplate reader (Labsystems, Thermo Fisher Scientific) with excitation and emission
wavelengths of 530 nm and 590 nm, respectively. The reaction was started with the addition
of 10 µM Amplex Red and 5 µM H2O2 using a multichannel pipette. The reaction progress
was monitored for 5 min, during which the reaction rate was linear. Fluorescence over the
5 min time span was reported as fluorescence (AU) per min.
2.11. Redox Potential Measurement
The midpoint redox potential (E0
′
) was analyzed spectrophotometrically by the equi-
libration method [24] using 2,6-dichloroindophenol (DCIP, E0
′
= 237 mV) as a reference
compound, which has an absorption band at 600 nm in its oxidized state. One hundred
µL of Cytc solution (2 mg/mL) were mixed in a spectrophotometric cuvette with 200 µL
of 50 mM citrate buffer (pH 6.5), 10 µL of 1 mM DCIP, and 2.5 µL of 1 mM K3Fe(CN)6 to
fully oxidize Cytc. Absorbance values corresponding to fully oxidized Cytc (A550-A570)
and DCIP (A600) were recorded using a Jasco V-570 double beam spectrophotometer. The
mixture was then sequentially reduced by adding 0.5 µL of 1 mM ascorbate (pH 6.5), and
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absorbance values were acquired at each step. When readings became constant, a few
grains of Na2S2O4 were added to fully reduce Cytc and DCIP. For each step, ratios of
oxidized and reduced forms of both compounds were calculated. Data obtained were
plotted as log(DCIPOX/DCIPRED) versus log(CytcOX/CytcRED), yielding a linear graph
with a slope of nDCIP /nCytc and a y-axis intercept of nCytc/59.2 (ECytc − EDCIP) as previ-
ously described [19]. These values were used to calculate the E0
′
(mV) of Cytc from the
Nernst equation.
2.12. Crystallization of K53Q Cytc
Cytc variants were further purified by gel filtration on a Sephacryl S-100 column
(GE healthcare). The protein was oxidized with 5 mM K3Fe(CN)6 to establish a defined
oxidation state before crystallization. Crystallization was done using basic crystallization
screens (Jena bioscience, Jena, Germany) with an approximate protein concentration of
15–20 mg/mL. Crystals were grown by vapor diffusion after mixing 1 µL of protein
solution with 1 µL of the reservoir solution and equilibrating the drop against 0.5 mL of
the precipitant at room temperature. The best diffracting crystals of K53Q mutant grew to
0.3 × 0.1 mm size in JBS1D4 condition which was 30% PEG 2K MME, 0.1 M MES 6.5, and
0.1 M Na-acetate. Crystals were soaked for 10 min in a cryoprotectant solution (20% v/v
ethylene glycol) before flash freezing in liquid nitrogen. Single crystal diffraction data were
collected at the Life Sciences Collaborative Access Team beamline 21-ID-D at the Advanced
Photon Source, Argonne National Laboratory. The data were collected over a full 360◦
rotation in either 0.6 or 1.0 frames and integrated using XDS [25] in AutoProc [26].
2.13. Statistical Analyses
Experimental data consisting of 3 or more replicates were analyzed for statistical
significance for the different experiments by one-way ANOVA followed by post hoc Tukey
test using GraphPad Prism version 8.4.3 (GraphPad software, San Diego, CA, USA). Data
are reported as means ± SEM and were considered statistically significant (*) with p < 0.05.
2.14. Molecular Dynamics
Molecular dynamics simulations were performed with YASARA version 20-07-04 [27]
using the conservative “slow” protocol and the recommended default forcefield, AMBER
2014 [28]. The starting structure for the molecular dynamics calculations on WT is from
molecule A in 5C0Z.PDB, which was obtained from oxidized Cytc in the presence of
potassium ferricyanide (K3[Fe(CN)6]), and the K53 mutants were all modeled from WT
molecule A. Root mean square fluctuation (RMSF) plots for the amino acid side chains
were generated with GraphPad using data imported from YASARA.
3. Results
3.1. Cytc Is Acetylated on Lysine 53 in Castrate-Resistant and Castrate-Sensitive Human Prostate
Cancer Xenografts
This is the first study to explore the role of Cytc PTMs in the context of cancer. As
there can be a time gap from the initial tumor resection or biopsy until pathological ex-
amination and cryopreservation of the clinical specimen, which can lead to the loss of
PTMs or their artificial introduction, we here chose the xenograft model. We implanted
castrate-resistant (PC3) and castrate-sensitive (VCaP) human prostate cancer cells in SCID
mice and harvested the xenografts when they reached a mass of about 800 mg. Sam-
ples were removed within 1 min and stored at −80 ◦C until use. As the available tissue
amount is small, a biochemical purification was not possible, and we instead enriched Cytc
by immunoprecipitation. Western blot analysis showed that Cytc from prostate cancer
xenografts are acetylated compared to recombinant human Cytc and Cytc immunoprecipi-
tated from normal human kidney tissue (Figure 1A). Cytc was also acetylated in cultured
PC3 and VCaP cells (Figure 1B). Furthermore, Cytc was acetylated in prostate cancer
tissues, whereas normal prostate tissue, lung cancer tissue, and MDA-MB-231 breast cancer
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cells did not indicate acetylation (Figure 1C). Next we performed mass spectrometry on
Cytc immunoprecipitated from a total of 8 prostate cancer xenografts (4 castrate-resistant
and 4 castrate-sensitive). We found that K53 of Cytc was acetylated in all 8 independently
grown prostate cancer xenografts (Figure 1D). Human Cytc has 18 lysine residues, however,
only K53 was found to be acetylated in these samples suggesting that K53 acetylation is a
highly specific modification.




Figure 1. (A) Cytc is acetylated in castrate-resistant (PC3) and castrate-sensitive (VCaP) prostate cancer xenograft tissues 
compared to normal human kidney tissue and recombinant human Cytc. (B) Cytc is acetylated in cultured PC3 and VCaP 
cells, but not acetylated in lung and kidney cancer tissues. (C) Cytc is acetylated in human prostate cancer tissues, but not 
acetylated in normal prostate tissue, lung cancer tissue, and MDA-MB-231 cells. (D) Mass spectrum of Cytc peptide 
TGQAPGYSYTAANK(acetyl)NK identifying Cytc K53 acetylation (underlined). This spectrum represents one 
immunoprecipitated castrate-sensitive tumor xenograft. The acetyl moiety was unambiguously assigned to this lysine via 
fragment ions y4+, y5+, etc., and b14+ containing 42 extra mass units for the acetyl group. The peptide sequence was 
unambiguously revealed by fragment ions b3+, b4+, b11+, b14+, y4+, y5+, y7+, y8+, y9+, y10+, y11+, y12+, and y13+. (E) 
Coomassie blue-stained gel showing the purity of recombinant Cytc overexpressed and purified from bacteria. All 4 Cytc 
variants displayed a single band on a 10% tris-tricine SDS-polyacrylamide gel at around 12 kDa. 
Figure 1. (A) Cytc is acetylated in castrate- esistan (PC3) and c ate-sensitive (VCaP) prostat ca ce xenograft tissues
compared to normal human kidney tissue and recombinant human Cytc. (B) Cytc is acetylated in cultured PC3 and
VCaP cells, but not acetylated in lung and kidney cancer tissues. (C) Cytc is acetylated in human prostate cancer tissues,
but not acetylated in normal prostate t ssue, lung cancer tissue, and MDA-MB-231 cells. (D) Mass spectrum of Cytc
peptide TGQAPGYSYTAANK(acetyl)NK identifying Cytc K53 acetylation (underlined). This spectrum represents one
immunoprecipitated castrate-sensitive tumor xenograft. The acetyl moiety was unambiguously assigned to this lysine
via fragment ion y4+, y5+, etc., and b14+ conta ning 42 extr mass units for the acetyl group. The peptide sequence was
unambiguously revealed by fragment ions b3+, b4+, b11+, b14+, y4+, y5+, y7+, y8+, y9+, y10+, y11+, y12+, and y13+. (E)
Coomassie blue-stained gel showing the purity of recombinant Cytc overexpressed and purified from bacteria. All 4 Cytc
variants displayed a single band on a 10% tris-tricine SDS-polyacrylamide gel at around 12 kDa.
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3.2. Purification of WT, Acetylmimetic, and Additional Cytc Control Variants
As the cost to grow enough xenografts to obtain preparative amounts of Cytc for
functional studies is prohibitive, we replaced the lysine residue with glutamine, which
mimics acetylated lysine. This mutation (K53Q) converts the positive charge of the lysine
side chain to a neutral charge, similar to the effect of lysine acetylation seen with the
acetylated protein in vivo. The bacterial pLW01 plasmid was used to generate WT and
acetylmimetic K53Q Cytc. We included two additional control mutants, K53R Cytc, which
carries a positive charge similar to non-acetylated lysine and nonpolar K53I. While K53 is
evolutionarily conserved across all mammals, K53I is the next most common replacement
at this site among species such as yeast and drosophila [29]. Recombinant WT, K53Q, K53R,
and K53I Cytc were overexpressed in bacteria and purified to homogeneity. The purified
proteins were resolved on an SDS-polyacrylamide gel and stained with Coomassie blue
(Figure 1E). All 4 proteins resulted in a single band around 12 kDa confirming the purity of
Cytc used for the functional assays.
3.3. K53Q Acetylmimetic Cytc Results in Reduced Cytochrome c Oxidase and Caspase 3 Activity
Compared to WT
Cancer metabolism is often characterized by increased glycolysis and decreased
mitochondrial respiration, leading to the Warburg effect [30]. To analyze the role of K53
acetylation in respiration, purified K53 Cytc variants were used to determine oxygen
consumption rate in the reaction with COX. Regulatory-competent COX was isolated
from bovine liver under conditions that preserve the in vivo phosphorylation state [31].
Oxygen consumption of 30 nM bovine liver COX was measured via titration (1–25 µM)
of purified Cytc variants in an Oxygraph system using a Clark-type oxygen electrode.
The experimental results showed that acetylmimetic K53Q and K53I Cytc resulted in a
lower oxygen consumption rate compared to WT and K53R Cytc (Figure 2A). At maximal
turnover, COX activity was reduced by about 35% in the presence of K53Q acetylmimetic
Cytc compared to the WT. The data suggest that K53 acetylation of Cytc downregulates
OxPhos, thus supporting Warburg metabolism. We studied the interaction of K53 Cytc
with COX using the published docking model [32] of COX and Cytc and found that K53 is
within 5 Å of lysine 58 residue of COX subunit VIIa (Figure 2C). This model suggests that
K53 is within the COX binding domain of Cytc and altering this residue or adding an acetyl
group could spatially interfere with optimal binding, resulting in decreased COX activity.
Cancer cells often manage to bypass cell death pathways, and evasion of apoptosis
is therefore another hallmark of cancer [8]. We analyzed the ability of K53 Cytc variants
to initiate apoptosis by measuring downstream caspase-3 activity. WT, K53Q, K53R, and
K53I recombinant Cytc proteins were incubated with cytosolic extracts isolated from HeLa
cells. Caspase-3 activity was determined by rhodamine fluorescence upon cleavage of the
rhodamine-linked DEVD tetrapeptide. Interestingly, acetylmimetic K53Q and nonpolar
K53I resulted in significantly 80% and 87% reduced caspase-3 activity, compared to the
WT (Figure 2B). Our control K53R Cytc even showed slightly increased caspase-3 activity,
suggesting that a positive charge is required for maximal caspase activation. A closer
analysis of the human apoptosome structure [33] shows that K53 is a part of the Apaf-1
binding domain of Cytc (Figure 2D). This further confirms that K53 serves as a regulatory
epitope for Apaf-1 binding and the activation of the caspase cascade and suggests an
underlying mechanism for evasion of apoptosis in prostate cancer through K53 acetylation.
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Figure 2. (A) Oxygen consumption rate was measured in the presence of 30 nM of bovine liver COX using an Oxygraph
system. WT, K53R, K53Q, and K53I Cytc variants were titrated at concentrations of 0, 1, 2, 3, 5, 10, 15, 20, and 25 µM (n = 3).
Data are represented as means±SEM. (B) Cytosolic extracts of HeLa cells were incubated with recombinant WT, K53R,
K53Q, and K53I variants for 2.5 h at 37 ◦C. Fluorescence that resulted from caspase-3 mediated cleavage of the rhodamine
substrate DEVD-R110 was used as a measure of caspase-3 activity (n = 3). Data are represented as means ± SEM, * p < 0.05.
(C) Docking model of COX and Cytc [32] showing the interaction of Lys53 residue of Cytc with Lys58 residue of COX
subunit VIIa within 5 Å. (D) Cytc Lys53 interaction with Apaf-1 represented on the human apoptosome structure [33].
Apaf-1 residues Phe1063 (within 5 Å) and Trp1007 and Thr1087 (within 6 Å) are in close proximity to Lys53 residue.
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3.4. Acetylmimetic Cytc Is a Superior ROS Scavenger
Cytc functions as a scavenger for both hydrogen peroxide and superoxide [34,35].
Considering the antioxidant role of Cytc, we determined the rate of Cytc oxidation upon
hydrogen peroxide addition and the rate of Cytc reduction upon superoxide production.
To determine the rate of Cytc oxidation, Cytc variants were reduced with sodium dithionite
and the ferro-Cytc variants were oxidized in the presence of 50 µM H2O2. K53Q undergoes
oxidation at about twice the rate compared to the WT and K53R Cytc controls, while
K53I mutant resulted in a 2.8-fold higher rate (Figure 3A). We next used the xanthine
oxidase/hypoxanthine system to generate superoxide [36] to analyze the superoxide
scavenging capacity of recombinant Cytc variants. Cytc was fully oxidized and reduction
of Cytc through electron transfer from superoxide was determined by spectrophotometer.
Interestingly, K53Q and K53I Cytc resulted in a 9- and 5-fold increase in superoxide
scavenging activity compared to WT Cytc (Figure 3B). These functional changes could add
to the pro-survival features of Cytc in prostate cancer by detoxifying ROS and lowering
apoptosis, as ROS are a major apoptotic trigger.
Figure 3. Cont.
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Figure 3. (A) Rate of oxidation of reduced Cytc 10 s after the addition of 50 µM H2O2 (n = 7). (B) Rate of reduction of
oxidized Cytc by superoxide produced in the presence of the hypoxanthine/xanthine oxidase reaction (n = 4–8). (C) Heme
degradation of Cytc upon addition of excessive H2O2 (3 mM) was measured as a reduction of absorbance in the 408 nm
Soret peak of Cytc (n = 3). (D) Liposomes containing 0%, 20%, 30%, and 50% of tetraoleoyl-cardiolipin (TOCL) were
incubated in the presence of Cytc K53 variants. Cardiolipin peroxidase activity was determined in the presence of H2O2 and
Cytc as a measure of resorufin fluorescence (n = 5). (E) Redox potential of K53 variants of Cytc were measured using the
spectrophotometric method in the presence DCIP as a reference compound (n = 5). Data are represented as means ± SEM, *
p < 0.05.
3.5. Acetylmimetic Cytc Is Less Stable at High H2O2 Concentrations and Shows Profoundly
Reduced Cardiolipin Peroxidase Activity
Cytc can lose its functionality at very high ROS concentrations. To test its stability, we
measured degradation of the heme catalytic site of Cytc upon addition of a high concen-
tration (3 mM) of H2O2. Dissipation of the Soret peak of Cytc at 408 nm is characteristic
of heme degradation. K53Q replacement resulted in the highest heme degradation of
73.8% at 800 s compared to WT, K53R, and K53I that resulted in a heme degradation of
57.6%, 53.3%, and 69.3%, respectively (Figure 3C). Cardiolipin is a mitochondria-specific
phospholipid which interacts with Cytc. The peroxidase activity of Cytc is activated in the
presence of H2O2, resulting in cardiolipin peroxidation. If this reaction happens on the
outer mitochondrial membrane, Cytc can be released from the mitochondria leading to
activation of apoptosis [3,4]. Cardiolipin peroxidase activity of Cytc variants was analyzed
by their efficiency in oxidizing cardiolipin, which in turn oxidizes Amplex red to resorufin.
Interestingly, cardiolipin peroxidase activity of acetylmimetic K53Q and nonpolar K53I
Cytc mutants were significantly reduced, by between 78% and 86%, compared to WT Cytc
at TOCL percentages of 20%, 30%, and 50% (Figure 3D). These findings align with caspase-3
activity data, further supporting an anti-apoptotic role for K53 acetylation. Finally, for
proper functioning of Cytc as an electron carrier, the redox potential of Cytc should be
between the redox potentials of complexes III and IV. In the literature, the mammalian Cytc
redox potentials are in the range of 220–270 mV [24,37]. The midpoint redox potential (E0
′
)
of K53 Cytc variants was measured spectrophotometrically. The redox potentials of the
Cytc variants were similar, 250 mV, 241 mV, 247 mV, and 261 mV for WT, K53R, K53Q, and
K53I Cytc, respectively (Figure 3E), suggesting that modification of K53 does not have a
major effect on the heme moiety.
3.6. Crystal Structure of K53Q Cytc at a Resolution of 1.31 Å
We have previously successfully crystalized WT and phosphomimetic Cytc vari-
ants [11,13] to explore possible structural changes and to draw structure and function
relationships. We used the same approach here and attempted to crystalize all three Cytc
mutants. Only the K53Q acetylmimetic mutant crystallized and gave a high-resolution
structure at 1.31 Å in space group P21212 with two independent monomers in the asym-
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metric unit. Structural data have been posted under the PDB code 7LJX. The crystallo-
graphic parameters for the K53Q structure are compared to those of the native mouse Cytc
(5C0Z.pdb) and the Y46F human Cytc (3ZOO.pdb) structures in Table 1. The components
in the crystal structure of the K53Q mutant that are within 3.5 Å of Q53 in molecules A
and B are presented (Figure 4A,B). The electron density for the two K53Q residues from an
unbiased “omit” map is shown at 1.0 sigma. The electron density for Q53 in molecule B is
better defined because its side chain is immobilized by a hydrogen bond to the carbonyl
oxygen of Y40. The side chain of Q53 in molecule A interacts only with a water molecule
within 3.5 Å. The crystal structure of K53Q Cytc (blue) was superposed onto the structure
of native (5C0Z.pdb) Cytc (green) using only the A-chains in both structures (Figure 4C,D).
The four independent chains in the native structure are labeled with lower case letters.
The two independent chains in the K53Q Cytc structure are labeled with capital letters.
The RMSD value for the superposed A-chains was 0.423 Å calculated from the backbone
atoms. The protein structures are depicted as Cα traces with the atoms in the hemes and the
ferrihexacyanide molecules represented by spheres. Figure 4C shows the front face of the
5C0Z tetramer in the P1 asymmetric unit. Figure 4D shows the edge of the tetramer after a
90◦ rotation about the vertical axis. When the two structures are superposed using only
the A-chains, the B-chain in the K53Q Cytc structure partially overlaps with the D-chain
in 5C0Z, but their relative orientation in the two crystal structures differs dramatically
(RMSD = 20.3 Å).
Table 1. Crystallographic data summarizing and comparing three structures of cytochrome c: Native, K53Q, and human Y46F.
Structure Cytc Mouse Cytc (K53Q) Mouse Cytc (Y46F) Human
PDB code 5C0Z 7LJX 3ZOO
Data code 141,118 × 21a 161,109 × 06a
CRYSTALLIZATION
Iron Oxidized Oxidized Oxidized
Protein
15 mg/mL Cytc (WT) + 5 mM
K3Fe(CN)6 in water
17mg/mL Cytc (K53Q) +
5 mM K3Fe(CN)6 in water
12.5 mg/mL oxidized Cytc in
22.5% (w/v) PEG-1000, 50 mM
KH2PO4, pH 7.0
Well 25% PEG 4K, 8% isopropanol,0.1 M Na Acetate, pH 6.5
30% PEG 2K MME, 0.1 M Na
MES, 0.1 M Na Acetate,
pH 6.5
26–31% (w/v) PEG 1000,
40 mM, KH2PO4. pH 7.0
Drop 1:1 Protein:Well 1:1 Protein:Well n/a
Cryoprotectant
30% PEG 4K, 8% isopropanol,
0.1 M Na Acetate, 20%
Ethylene glycol, 10 min soak
with 5 mM K3Fe(CN)6, final
pH 6.5
35% PEG 2K MME, 0.1 M Na
MES, 0.1 M Na Acetate, pH
6.5, 20% Ethylene glycol
26–31% (w/v) PEG 1000,
40 mM, KH2PO4, 15%
Glycerol, pH 7.0
CRYSTAL DATA
Space group: P1 P2(1)2(1)2 P1
Unit cell: a 34.401 52.837 36.367
b 52.471 96.767 53.952
c 61.647 38.372 58.95
Alpha 110.04 90 76.55
Beta 92.77 90 88.73
Gamma 92.02 90 71.86
Chains per A.U. 4 2 4
Matthews Coeff 2.24 2.1 2.3
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Structure Cytc Mouse Cytc (K53Q) Mouse Cytc (Y46F) Human
Solvent % 45.12 41.4 46.7
X-RAY DATA
Resolution-high (Å) 1.12 1.31 1.35
Resolution-low (Å) 49.22 48.38 30.59
Beamline APS 21-ID-F APS 21-ID-D DIAMOND 103 (UK)
Wavelength 0.97872 1.07822 0.9762
Reflections 127840 48257 81707
Completeness 87.4 (44.7) 98.9 (86.8) 94.7 (80.7)
Average I/sigma 14.4 (2.0) 12.2 (2.1) 8.70 (n/a)
Redundancy 3.9 (3.7) 11.1 (6.6) n/a
Resolution-high (Å) 1.12 1.31 1.35
Resolution-low (Å) 49.22 48.38 30.59
Rmerge 0.050 (0.548) 0.120 (0.821) 0.07
REFINEMENT
Rfactor 0.132 (0.239) 0.138 (0.291) 0.138
Rfree 0.159 (0.240) 0.170 (0.316) 0.179
Avg B-factor (Å2) 15.97 21.32 17.703
Protein atoms per A.U. 3228 1614 3981
Water molecules 537 194 417
Bond RMSD 0.017 0.016 0.017











C14 SG—HEM CAB 1.90 (0.04) 1.77 (0.01) 1.95 (0.02)
C17 SG—HEM CAC 1.98 (0.04) 1.86 (0.00) 2.13 (0.07)
H18 NE2—FE2 (Å) 2.02 (0.01) 1.99 (0.01) 2.02 (0.03)
M80 SD—FE2 (Å) 2.30 (0.01) 2.31 (0.01) 2.28 (0.02)
The RMSD plot comparing the two independent K53Q molecules (7LJX.pdb) with
molecule A in the native Cytc structure (5C0Z.pdb) shows a significant difference—exhibited
by both K53Q molecules—at residues R38 and Q42 (Figure 4E). These two residues plus the
three intervening residues have a total of 4 contacts within 4 Å with two adjacent dimers in
the crystal. One of the crystal interfaces is reciprocal—K39 in the central dimer is within
4Å of K39 in the adjacent dimer.
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Figure 4. (A,B) The comparison of the “omit” density for K53Q in the two Cytc molecules in the asymmetric unit of the
crystal structure. (C,D) The structure of the K53Q Cytc crystallographic dimer is superposed onto the native rodent Cytc
(5C0Z.pdb) crystallographic tetramer using chain-A in both structures. (E) C-alpha atom RMSD plots of K53Q Mol-A and
Mol-B relative to Mol-A in the WT structure (5C0Z.pdb).
3.7. Molecular Dynamics Simulations
Molecular dynamics calculations were performed on four Cytc variants (WT, K53R,
K53Q, and K53I) using YASARA version 20-07-04 with its conservative “slow” protocol and
the default forcefield, AMBER 2014. Each dynamics calculation was run for 700 ns—the
same as our recent study on the phosphomimetic, T58E Cytc [12]. The residue RMSF values
for the 600 ns and 700 ns blocks for WT and the three mutants were compared in this study
(Figure 5). The two blocks are similar for WT, K53Q, and K53I, which indicates that the
calculations have reached equilibrium. The K53R model has significantly less mobility in
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the loop consisting of amino acid residues 20–30 at 700 ns than at 600 ns. All four plots in
Figure 5 show significant mobility (>2.5 Å) between residues 20–30 and at the C-terminus.
The other site with RMSF values approaching 2 Å consist of residues 81–90. Met80 is
tethered to the heme iron atom. Similar patterns were observed for the T58 mutants [12].
Although Figure 4E shows significant RMSD differences between the WT and K53Q crystal
structures at residues 38 and 42, the RMSF values are relatively small (Figure 5A,C).
Figure 5. Molecular dynamics simulations. All four simulation averages were calculated for the 500–600 ns (blue) and
600–700 ns (red) intervals. The average RMSF (Å) for all atoms in each residue in the amino acid chains are shown. All four
runs displayed equilibrium within 500 ns to 700 ns. (A) Molecule A from the WT Cytc crystal structure (PDB entry 5C0Z).
(B) Equivalent to (A) for K53R Cytc. (C) Equivalent to (A) for K53Q Cytc. (D) Equivalent to (A) for K53I Cytc.
4. Discussion
In this study, we discovered that K53 acetylation of Cytc is a prostate cancer specific
modification that may contribute to the underlying mechanisms of cancer. This mod-
ification was present in both castrate-sensitive and castrate-resistant tumor xenografts,
suggesting that K53 acetylation of Cytc plays a role in prostate cancer pathogenesis regard-
less of hormone sensitivity of the tumor. Cytc is a highly positively charged protein that
has 18 lysine residues which account for over one-sixth of the protein. Lysine acetylation
is the most common PTM of the mitochondria, and in particular in the matrix [38,39].
The pumping of protons across the inner mitochondrial membrane (IMM) to generate the
proton-motive force results in a more basic pH between 7.9 and 8.0 in the mitochondrial
matrix, compared to other compartments such as the cytosol and nucleus (pH 7.2) [40].
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The basic pH and the abundance of acetyl-CoA creates a more favorable environment for
non-enzymatic protein lysine acetylation in the mitochondrial matrix [41,42].
However, Cytc is located in the IMS with a more acidic pH compared to the ma-
trix. Strikingly, K53 was consistently acetylated in all 8 prostate cancer xenograft samples
subjected to mass spectrometry analysis, making it a highly specific modification. Cytc
immunoprecipitated from prostate cancer and prostate cancer cell lines was also acetylated,
whereas Cytc from normal prostate, lung cancer, normal and kidney cancer tissues, and
a breast cancer cell line was not acetylated. It should also be noted that phosphoryla-
tions, which we have reported in healthy tissues and have been shown to regulate the
multiple functions of the protein [9–13,43–48], were not detected in any of the prostate
tumor xenografts. This indicates a dichotomy between signaling pathways in normal
and transformed cells that target Cytc. Additionally, K53 of Cytc is conserved across all
mammals [29], pointing to a central regulatory site.
Cell signaling by PTMs is one of the most common modes of regulation in higher
organisms that is dysregulated in cancer. The two hallmarks of cancer, metabolic repro-
gramming and evasion of apoptosis, could at least in part be explained by Cytc acetylation.
Cancer cells undergo metabolic reprogramming that often results in reduced OxPhos activ-
ity, which together with parallel upregulation of glycolysis allows fast ATP production and
provides metabolites for biosynthesis for cancer cell proliferation [7,49,50]. Cytc is also a
central player in apoptosis and has several other functions such as ROS scavenging, which
could be exploited by cancer cells. Therefore, in order to characterize K53 acetylation, we
used an acetylmimetic substitution, K53Q. This is a well-established method for studying
acetylation in vitro [51]. The advantages of this approach are that the modification cannot
be lost during functional assays and that large amounts of the protein can be generated
by bacterial overexpression for functional analyses. In addition to K53Q, we assessed the
function of WT, K53R, and K53I variants of Cytc. WT and K53R carry a positive charge at
residue 53, whereas K53Q and K53I are polar and neutral, respectively, but do not carry a
charge. Consequently, in most assays, K53Q and K53I behaved in a similar manner.
This reaction between Cytc and COX is the proposed rate-limiting step of the ETC
under physiological conditions where 90% of cellular oxygen is consumed [52]. K53Q
acetylmimetic replacement resulted in significantly lower oxygen consumption in reaction
with COX compared to WT and K53R. Therefore, our results suggest that K53 acetylation
plays a role in metabolic reprogramming by lowering ETC activity. Our results further
suggest that K53 acetylation of Cytc may lead to evasion of apoptosis by hindering apop-
tosome formation and activation. Interestingly, additional pro-survival effects of K53Q
acetylmimetic replacement are increased ROS scavenging and decreased cardiolipin per-
oxidase activity. Oxidative stress mediated by ROS such as superoxide and H2O2 are
considered triggers of apoptosis [53]. K53Q Cytc showed increased ability to scavenge both
superoxide and H2O2. However, the role of ROS in cancer is complicated and cancer stage
specific. In certain stages increased ROS levels can also promote cancer as, for example,
has been shown for ROS scavenger manganese superoxide dismutase (MnSOD), which
can act both as a tumor suppressor and a promoter [54]. Cardiolipin peroxidase activity
is also classified as a pro-apoptotic function [55]. Lower cardiolipin peroxidase activity
in the presence of K53Q Cytc suggests that less Cytc is available to be released from the
mitochondria into the cytosol to activate apoptosis when Cytc is acetylated at K53.
Of the new mutants studied here only the K53Q Cytc mutant crystallized and gave
a high-resolution structure at 1.31 Å that showed good omit map density for Q53 and
confirmed that the mutation caused no major structural disturbance or unfolding at its
location, although there is a moderate distortion at R38-Q42 due to crystal packing. Inter-
estingly, molecular dynamics simulations revealed that K53Q has increased flexibility at
the T28 epitope, a loop previously shown to be an important regulatory domain [11]. We
propose that the increased mobility of this loop may explain the increased ROS scavenging
activities of acetylmimetic Cytc due to a more flexible and thus open structure, allowing
easier access of superoxide and H2O2 to the heme group. We also showed that K53Q Cytc
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undergoes faster heme degradation in the presence of excessive H2O2, which is consistent
with our interpretation of better access of the oxidant to the heme group. A previous study
with T28A Cytc also showed a similar pattern both functionally and in molecular dynamics
simulations [11], assigning an important regulatory and stability function to the T28 loop.
In conclusion, our studies suggest that K53 acetylation is a pro-cancer modification by
lowering COX activity and caspase-3 activity and by increasing ROS scavenging. To our
knowledge, this is the first report characterizing a specific Cytc acetylation. We propose
that K53 acetylation of Cytc contributes to cancer pathogenesis by promoting Warburg
metabolism and evasion from apoptosis. However, these mechanisms should be further
confirmed in a cell culture system and in vivo. Furthermore, there is an ongoing debate
with regard to OxPhos activity in prostate cancer. Some studies suggest an increase in
OxPhos activity [56–58] while others suggest a decrease in mitochondrial respiration with
increasing malignancy [59–61]. Therefore, more emphasis should be given to the anti-
apoptotic role of Cytc K53 modification in prostate cancer cells. A recent study showed that
abrogation of apoptosome-mediated caspase activation and defective release of Cytc from
the mitochondria are associated with prostate cancer aggressiveness observed in African
American men [62], further supporting an important role of Cytc as a cancer driver. Other
studies have shown that acetyltransferases mediating protein acetylation are upregulated
in prostate cancer [63,64] and could be established as rational therapeutic targets [65,66].
Therefore, a better mechanistic understanding of Cytc acetylation in prostate cancer and
potentially other cancers may allow the development of novel effective cancer therapeutics
that target Cytc for the first time.
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